RETRACTED: Association between the Platelet-Derived Growth Factor/Platelet-Derived Growth Factor Receptor System and Risk of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis (Retracted Article)

被引:2
作者
Li, Feiyan [1 ]
Wu, Shaoping [2 ]
Xie, Hualing [1 ]
Wang, Wanling [3 ]
Wang, Jing [1 ]
Jia, Chanyi [1 ]
Xie, Chao [4 ]
Zhang, Xia [3 ]
机构
[1] Chongqing Hosp Tradit Chinese Med, Dept Rheumatol, Chongqing 400021, Peoples R China
[2] Chongqing Hosp Tradit Chinese Med, Dept Cardiol, Chongqing 400021, Peoples R China
[3] Chongqing Hosp Tradit Chinese Med, Dept Endocrinol, Chongqing 400021, Peoples R China
[4] Chongqing Hosp Tradit Chinese Med, Clin Support Ctr, Chongqing 400021, Peoples R China
关键词
EXPRESSION; CYTOKINES; CELLS; PROLIFERATION; INCREASES;
D O I
10.1155/2022/6221673
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This research examines the association between the platelet-derived growth factor/platelet-derived growth factor receptor (PDGF/PDGFR) system and rheumatoid arthritis (RA) susceptibility through a comprehensive search of the PubMed database to study the expression of the PDGF/PDGFR system in RA. Review Manager software version 5.3 was used for statistical analysis. Six eligible studies published in the English language were included, including 108 rheumatoid arthritis cases and 85 controls with the corresponding 126 and 97 tests, respectively, relating the expression of the PDGF/PDGFR system to the risk of RA. The overall results indicated a significant association between the PDGF/PDGFR system expression and RA (OR=5.25, 95% CI: 3.00-9.18, p < 00001), RA patients in Asian countries (OR=4.13, 95% CI=2.04-8.39, p < 0.0001) and in Western countries (OR=9.18, 95% CI=2.04-8.39, p=0.03), and only PDGF expression in RA patients (OR=5.28, 95% CI=2.73-10.21, p < 0.00001). Thus, only the PDGFR expression was insignificantly associated with RA susceptibility (OR=9.25, 95% CI=0.63-136.30, p=0.11). Hence, the PDGF/PDGFR system most likely contributes to susceptibility to RA.
引用
收藏
页数:8
相关论文
共 32 条
  • [1] Cytokines in the pathogenesis of rheumatoid arthritis: New players and therapeutic targets
    Alunno A.
    Carubbi F.
    Giacomelli R.
    Gerli R.
    [J]. BMC Rheumatology, 1 (1)
  • [2] Role of platelet-derived growth factors in physiology and medicine
    Andrae, Johanna
    Gallini, Radiosa
    Betsholtz, Christer
    [J]. GENES & DEVELOPMENT, 2008, 22 (10) : 1276 - 1312
  • [3] Methotrexate inhibits effects of platelet-derived growth factor and interleukin-1β on rheumatoid arthritis fibroblast-like synoviocytes
    Bergstrom, Beatrice
    Carlsten, Hans
    Ekwall, Anna-Karin Hultgard
    [J]. ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [4] Platelet-Derived Growth Factor Receptor Activation Promotes the Prodestructive Invadosome-Forming Phenotype of Synoviocytes from Patients with Rheumatoid Arthritis
    Charbonneau, Martine
    Lavoie, Roxane R.
    Lauzier, Annie
    Harper, Kelly
    McDonald, Patrick P.
    Dubois, Claire M.
    [J]. JOURNAL OF IMMUNOLOGY, 2016, 196 (08) : 3264 - 3275
  • [5] Platelet-derived growth factor-AA increases IL-1β and IL-8 expression and activates NF-κB in rheumatoid fibroblast-like synoviocytes
    Cheon, H
    Sun, YK
    Yu, SJ
    Lee, YH
    Ji, JD
    Song, GG
    Lee, JH
    Kim, MK
    Sohn, J
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2004, 60 (05) : 455 - 462
  • [6] Role of cytokines in rheumatoid arthritis
    Feldmann, M
    Brennan, FM
    Maini, RN
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 : 397 - 440
  • [7] New therapies for rheumatoid arthritis
    Goldblatt, F
    Isenberg, DA
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 140 (02) : 195 - 204
  • [8] Guo Q, 2018, BONE RES, V6, DOI [10.1038/s41413-018-0016-9, 10.1163/24689246-00101001]
  • [9] Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor
    Kameda, H
    Ishigami, H
    Suzuki, M
    Abe, T
    Takeuchi, T
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2006, 144 (02) : 335 - 341
  • [10] Kameda H, 2007, DRUG TARGET INSIGHT, V2, P239